The initial public offering (IPO) of Sai Parenterals began on a subdued note, with the issue receiving only about 4% subscription on the first day of bidding.
Data shows that the IPO attracted limited bids compared to the total shares on offer, reflecting cautious investor sentiment. The weak response comes at a time when market participants are increasingly selective in the primary market.
The ₹409 crore issue, which opened on March 24 and will close on March 27, includes both a fresh issue of shares and an offer for sale. The company has fixed a price band of ₹372 to ₹392 per share.
Market signals also indicate a lack of strong enthusiasm. The grey market premium (GMP), often seen as an indicator of listing gains, remains flat, suggesting expectations of a modest or neutral debut on the stock exchanges.
Analysts attribute the slow start to a combination of factors, including valuation concerns and overall market uncertainty. Investors are closely evaluating company fundamentals and growth potential before committing funds, particularly in mid-sized IPOs.
The pharmaceutical sector, while generally stable, has seen mixed interest in recent public issues, further contributing to the cautious approach among investors.
The company plans to use the funds raised for expansion, working capital needs and general corporate purposes. However, experts advise potential investors to review the firm’s financials and long-term outlook before making decisions.
Despite the muted opening, subscription levels could improve in the coming days, as institutional investors and retail participants often step in closer to the closing date.
Also Read: Oil prices drop on Iran negotiation talks